Bevetex is a chemotherapeutic medication used in the treatment of various types of cancer, including breast cancer, ovarian cancer, non-small cell lung cancer, and pancreatic cancer. It contains Paclitaxel as the active ingredient, a cytotoxic agent derived from the Pacific yew tree. Paclitaxel works by stabilizing microtubule polymerization, which inhibits cell division and leads to cancer cell death.

Paclitaxel is a vital drug in the management of various cancers. While it is effective in slowing or stopping cancer progression, its use requires careful monitoring due to its significant side effects and potential toxicity. Always consult an Oncologist for appropriate dosing and safety measures.

Mechanism of Action:

• Paclitaxel stabilizes the microtubules in cells, preventing their disassembly. This action disrupts the normal process of cell division (mitosis), resulting in the inhibition of cancer cell growth and promoting apoptosis (programmed cell death).

Indications: Paclitaxel is indicated for the treatment of:

• Breast cancer

• Ovarian cancer

• Non-small cell lung cancer

• Kaposi’s sarcoma associated with AIDS

• Pancreatic cancer

Dosage and Administration: Paclitaxel is administered as an intravenous (IV) infusion. The dosage depends on the type and stage of cancer, patient’s body surface area (BSA), and response to treatment. Common regimens include:

• For breast cancer: 175 mg/m² over 3 hours every 3 weeks

• For non-small cell lung cancer: 135 mg/m² over 24 hours followed by cisplatin every 3 weeks

• Dose adjustments may be required based on patient tolerance and laboratory parameters.

Side Effects:
Common side effects include:

• Nausea and vomiting

• Hair loss (alopecia)

• Decreased blood cell counts (neutropenia, anemia)

• Peripheral neuropathy (numbness or tingling in hands and feet)

• Joint and muscle pain

Serious side effects may involve:

• Severe allergic reactions

• Heart problems such as arrhythmias

• Liver toxicity

Warnings and Precautions:

• Use under strict medical supervision.

• Pre-treatment with corticosteroids, antihistamines, and H2 antagonists is recommended to reduce the risk of hypersensitivity reactions.

• Avoid in patients with severe liver impairment.

• Pregnant or breastfeeding women should not use Paclitaxel due to the risk of harm to the fetus or infant.

Drug Interactions:

• Concomitant use with cisplatin increases the risk of neurotoxicity.

• Paclitaxel metabolism may be affected by medications that induce or inhibit CYP2C8 and CYP3A4 enzymes.

Storage:

• Store Paclitaxel injections at controlled room temperatures (20°C to 25°C) and protect from light.